At least three strategies to decrease the circulating sFlt-1 level in patients with preeclampsia can be considered10: (1) a decrease in sFlt-1 gene expression at the transcriptional level, (2) removal of the sFlt-1 protein from the blood circulation of patients with preeclampsia using a method, such as apheresis, and (3) supplementation of an appropriate amount of angiogenic factor, such as VEGF, which is trapped by the up-regulated sFlt-1 molecule. The gene discussed is VEGFA; the disease is preeclampsia.